Effects of Angiotensin Receptor Blockers on Kidney Function in Patients with Diabetes and Hypertension

Mechanisms of ARB Action on the Kidney

ARBs block the angiotensin II type 1 (AT1) receptor, reducing intraglomerular pressure and proteinuria through mechanisms independent of their blood pressure-lowering effects, as noted by the American Diabetes Association 1, 2
ARBs decrease albuminuria and slow the decline in glomerular filtration rate (GFR) in patients with established chronic kidney disease (CKD), particularly those with diabetes and macroalbuminuria, according to the American Journal of Kidney Diseases 2, 3
The renoprotective effects of ARBs include reduced oxidative stress in the kidney and decreased NLRP3 inflammasome activity, which contribute to their kidney-protective properties, as reported by the Diabetes Care journal 4

ARBs are more effective than other antihypertensive classes (except ACE inhibitors) in slowing kidney disease progression in patients with type 2 diabetes and macroalbuminuria, as stated by the American Journal of Kidney Diseases 3
In patients with type 2 diabetes and normal urinary albumin excretion, ARBs can reduce or suppress the development of albuminuria, though one trial noted increased cardiovascular events, according to the Diabetes Care journal 2
The American College of Cardiology recommends ARBs as the preferred first-line agents for blood pressure treatment in patients with diabetes, hypertension, eGFR <60 mL/min/1.73 m², and UACR ≥300 mg/g creatinine due to their proven benefits for preventing CKD progression 2, 5

The American Heart Association suggests that ARBs are useful for managing blood pressure but have not proven superior to alternative antihypertensive classes like thiazide-like diuretics and dihydropyridine calcium channel blockers in patients without kidney disease, as noted by the Diabetes Care journal 2, 6
In patients with lower levels of albuminuria (30-299 mg/g creatinine), ARB therapy at maximum tolerated doses has been shown to reduce progression to more advanced albuminuria, slow CKD progression, and reduce cardiovascular events, according to the Diabetes Care journal 2, 6

The American College of Physicians recommends that ARBs should be titrated to the maximum tolerated dose with close monitoring of serum potassium and creatinine within 2-4 weeks of initiation or dose change, as stated by the Annals of Internal Medicine 5
Clinical trials demonstrating efficacy used maximum tolerated doses, and concerns about rising serum creatinine often lead to suboptimal ARB dosing, as reported by the Diabetes Care journal 7, 2
ARBs can be continued even when serum creatinine increases by up to 30% without associated hyperkalemia, as this initial change does not indicate harm, according to the Annals of Internal Medicine and the Diabetes Care journal 5, 2

The combination of ACE inhibitors and ARBs should be avoided due to higher adverse event rates (hyperkalemia and/or acute kidney injury) without additional benefits on cardiovascular or CKD outcomes, as noted by the Diabetes Care journal and the Praxis Medical Insights 2, 1

ARBs improve renal perfusion primarily by dilating both afferent and efferent arterioles, with a relatively greater effect on efferent arterioles, which reduces intraglomerular pressure while increasing overall renal blood flow 8, 9
By blocking the effects of angiotensin II, ARBs cause vasodilation of renal arterioles, which improves blood flow and protects renal perfusion 10
ARBs have a relatively greater dilating effect on postglomerular efferent arterioles than on afferent arterioles, which reduces glomerular capillary pressure while maintaining or increasing renal blood flow 8, 11

Total renal vascular resistance decreases with ARB administration, leading to an increase in renal blood flow (RBF) in most patients 8, 11
Despite the increase in renal blood flow, glomerular filtration rate (GFR) usually remains unchanged or falls slightly due to the reduction in intraglomerular pressure 8, 9
ARBs reduce endothelin-1 and thromboxane prostaglandins that promote vasoconstriction, contributing to renal vasodilation 10

ARBs can cause a predictable increase in serum creatinine (up to 20%) due to their effect on intraglomerular hemodynamics, which is generally considered an acceptable physiological response 10
The renoprotective effects of ARBs are evident in their ability to reduce albuminuria and slow the decline in GFR in patients with diabetic nephropathy 12
ARBs are particularly effective in reducing progression of kidney disease in patients with type 2 diabetes and macroalbuminuria compared to other antihypertensive classes 12

ARBs may precipitate acute renal failure in specific clinical scenarios, such as when mean arterial pressure (MAP) falls below levels needed for adequate renal perfusion (typically <55 mmHg) 8, 9
ARBs may also precipitate acute renal failure in volume-depleted patients, particularly those on diuretic therapy 8, 9
The risk of ARB-induced acute kidney injury is higher in patients with pre-existing chronic renal insufficiency 9

Combination of ARBs with ACE inhibitors should be avoided due to increased risk of adverse events (hyperkalemia and/or acute kidney injury) without additional benefits 13